April 2022 – Page 2 – cannabis.co.nz

April 21, 20227, adult use, analysis, analytics, applicant, application, business, Business Analysis, cannabis, Cannabis Regulatory Commission, commission, companies, compliance, CQC, CQCExpo, CRC, cultivation, customer, dispensaries, Dispensaries & Retail, dispensary, diversity, government, growing, industry, large, law, legal, legalization, legalize, legislation, license, licensee, licenses, licnesing, marijuana, market, medical, medicine, multi state operator, new jersey, NJ, Operations, patient, process, product, recreational, regulation, regulations, regulatory, retail, sale, sales, selling, small, social equity, state, thc

New Jersey Launches Adult Use Sales

On Thursday, April 21, a handful of dispensaries in New Jersey begin selling cannabis to adults over the age of 21. The […]

April 21, 2022Aaron Green, Act, aeropay, analysis, analytics, ATM, automated, bank, banking, business, Business Analysis, cannabis, card, cash, cashless, Cathy Corby Iannuzzelli, CEO, compliance, compliant, consumer, credit, Daniel Muller, Debit, dispensaries, executive, Federal, finance, financial, financing, founder, government, growing, industry, Iridium consulting, KindTap, law, legal, legalization, legalize, legislation, license, marijuana, market, Operations, pay, payment, president, process, processing, processor, product, recreational, regulation, regulations, regulatory, retail, retailer, safe, state, tax, taxes, tech, technologies, transaction

State of the US Cannabis Payment Processing Market: An Interview with Executives at KindTap and Aeropay

Federal regulations have made compliant credit processing in the cannabis industry difficult to achieve. As a result, most cannabis retailers operate a […]

April 20, 2022action, analysis, analytics, approval, approved, business, Business Analysis, cannabidiol, cannabis, cbd, claim, compliance, Concentrates & Extracts, consumer, Coronavirus, COVID, COVID-19, cultivation, drug, Edibles & Processing, enforcement, extraction, farm bill, FD&C act, FDA, Federal, government, growing, Health, industry, lab, law, legal, legalization, legalize, legislation, letter, license, marijuana, market, medical, medicine, New, product, Product Development, Quality, regulation, regulations, regulatory, research, retail, safety, state, test, Testing, thc, threaten, U.S. Food and Drug Administration, unapproved, unsubstantiated, warning, wellness

FDA Warning Letters: Stop Claiming CBD Prevents COVID

Once again, the U.S. Food and Drug Administration (FDA) has issued a number of warning letters to companies selling hemp-derived cannabidiol (CBD) […]